Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

被引:16
|
作者
Keefe, Richard S. E. [1 ]
Harvey, Philip D. [2 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
[2] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA
关键词
schizophrenia; clinical trials; cognition;
D O I
10.1093/schbul/sbn042
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. These issues are likely to be magnified in future studies when cognitive neuroscience (CN) procedures are explored in these trials, because in their current forms CN procedures are less standardized and more difficult to teach and monitor. For multisite trials, we anticipate that the most challenging issues will include assuring tester competence, monitoring tester performance, specific challenges with complex assessment methods, and having resources available for adequate monitoring of data quality. Suggestions for overcoming these implementation challenges are offered.
引用
收藏
页码:656 / 663
页数:8
相关论文
共 50 条
  • [31] Clinical trials: Considerations for researchers and hospital administrators
    Uecke, Oliver
    Reszka, Regina
    Linke, Joachim
    Steul, Martina
    Possel, Thorsten
    HEALTH CARE MANAGEMENT REVIEW, 2008, 33 (02) : 103 - 112
  • [32] CLINICAL TRIALS IN DEVELOPING COUNTRIES - ETHICAL CONSIDERATIONS
    Pasic, Marija Bosnjak
    Vidrih, Branka
    Sarac, Helena
    Pasic, Hanna
    Vujevic, Luka
    Koruga, Anamarija Soldo
    Rajic, Fabijan
    PSYCHIATRIA DANUBINA, 2018, 30 (03) : 285 - 291
  • [33] Brain phylogeny, ontogeny and dysfunction: integrating evolutionary, developmental and clinical perspectives in cognitive neuroscience
    Hannan, Anthony J.
    ACTA NEUROPSYCHIATRICA, 2007, 19 (03): : 149 - 158
  • [34] Adapting Social Neuroscience Measures for Schizophrenia Clinical Trials, Part 3: Fathoming External Validity
    Olbert, Charles M.
    Penn, David L.
    Kern, Robert S.
    Lee, Junghee
    Horan, William P.
    Reise, Steven P.
    Ochsner, Kevin N.
    Marder, Stephen R.
    Green, Michael F.
    SCHIZOPHRENIA BULLETIN, 2013, 39 (06) : 1211 - 1218
  • [36] Standardizing in vitro diagnostics tasks in clinical trials: a call for action
    Lippi, Giuseppe
    Simundic, Ana-Maria
    Rodriguez-Manas, Leocadio
    Bossuyt, Patrick
    Banfi, Giuseppe
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (09)
  • [37] Ethical considerations related to the inclusion of women in clinical trials
    Fullerton, JT
    Sadler, GR
    JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2004, 49 (03) : 194 - 202
  • [38] Clinical trials and sample size considerations: Another perspective
    Lee, SJ
    Zelen, M
    STATISTICAL SCIENCE, 2000, 15 (02) : 95 - 103
  • [39] Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
    Zhao, Yan D.
    Dmitrienko, Alex
    Tamura, Roy
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (01): : 72 - 83
  • [40] Review Article: Ethical Considerations in Conducting Clinical Trials
    Mousavinejad, Shahriar
    Bazmi, Shabnam
    Rezaei-Tavirani, Mostafa
    Shamsi-Gooshki, Ehsan
    Enjoo, Seyed Ali
    Kiani, Mehrzad
    INTERNATIONAL JOURNAL OF MEDICAL TOXICOLOGY AND FORENSIC MEDICINE, 2021, 11 (04): : 34863